Novo Nordisk recruits 500 people for Alzheimer's trial
Alzheimer’s has been called the graveyard of the pharmaceutical industry, and many companies have failed within the indication. Still, signs indicate that Novo Nordisk has a chance of success with its GLP-1 approach, and Lundbeck’s head of R&D says there’s ”relatively strong reasoning behind it.”
BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
The world’s biggest pharmaceutical firms have been trying for decades. Danish Lundbeck is having a go, and recently, Novo Nordisk threw its hat in the ring.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen and Eisai change agreements on Alzheimer's drug
For subscribers
.jpg&w=384&q=75)
